CSIMarket
 
Asensus Surgical Inc   (ASXC)
Other Ticker:  
 
 
Price: $0.2800 $-0.01 -3.114%
Day's High: $0.2901 Week Perf: -5.56 %
Day's Low: $ 0.28 30 Day Perf: -4.44 %
Volume (M): 523 52 Wk High: $ 0.86
Volume (M$): $ 147 52 Wk Avg: $0.39
Open: $0.29 52 Wk Low: $0.20



 Market Capitalization (Millions $) 72
 Shares Outstanding (Millions) 256
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -79
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 1

Asensus Surgical Inc
Asensus Surgical Inc is a medical technology company that specializes in the development of surgical robotic systems. Their flagship product, the Senhance Surgical System, is designed to assist surgeons in performing minimally invasive surgery with improved precision and control. The system integrates robotic arms with instruments that can be controlled by the surgeon from a console. This allows for enhanced dexterity and flexibility during procedures. Asensus Surgical Inc aims to improve patient outcomes and reduce healthcare costs through their innovative robotic technology.


   Company Address: 1 TW Alexander Drive, Suite 160 Durham 27703 NC
   Company Phone Number: 765-8400   Stock Exchange / Ticker: NYSEAMER ASXC
   ASXC is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Innovating Surgeon-Patient Interaction: Asensus Surgical Celebrates 1,000 Successful Senhance Cases across Three Global Hospitals

Published Tue, Feb 27 2024 11:55 AM UTC

In an era of advancing medical technologies, Asensus Surgical, Inc. (NYSE American: ASXC) is leading the way in digitizing the surgeon-patient interface. The company recently achieved a significant milestone, completing over 1,000 successful cases at three renowned hospitals globally. Utilizing the innovative Senhance Surgical System, these hospitals include Klaipeda Univers...

Product Service News

Asensus Surgical Inc Expands Reach with Sale of Senhance Robotic System in Romania, Revolutionizing Pediatric Surgery

Published Wed, Dec 20 2023 11:55 AM UTC

Asensus Announces Sale of Senhance Robotic System in Romania
Timisoara, Romania - Asensus Surgical Inc, a leading medical technology company, has recently made an exciting announcement regarding the sale of their Senhance Robotic System to a pediatric hospital in Timisoara, Romania. This development marks a significant milestone for both Asensus Surgical Inc and the medi...

Asensus Surgical Inc

Asensus Surgical Inc

Asensus Surgical Inc, formerly known as TransEnterix Inc, is a medical technology company that focuses on the development and commercialization of robotic surgical systems. The company's flagship product, the Senhance Surgical System, is designed to enhance the capabilities of surgeons and improve patient outcomes.
In the third quarter of 2023 earnings season, Asensus Surgical Inc reported a decrease in the loss per share from $-0.08 to $-0.07 compared to the same period a year prior. Furthermore, earnings per share improved from $-0.09 in the previous reporting period. However, the company experienced a sharp drop in revenue, with a decrease of -91.416% to $0.22 million from $2.56 million in the corresponding reporting period a year ago. Sequentially, the revenue tumbled by -78.153% from $1.01 million.

Asensus Surgical Inc

Medical Equipment & Supplies Company Faces Larger Shortfall in Q2 2023 - a 12% Increase from Last Year\Asensus Surgical Inc's Stock Plummets 41.96% in 5 Days - Company Reports Continued Deficit in Q2 2023

During the past 5 trading days, Asensus Surgical Inc's stock has experienced a significant drop of -41.96%. This decline has contributed to a year-to-date performance of -14.47% for the company. However, despite this recent decrease, the stock is still trading 9.1% above its 52-week low.
Looking at the financial performance of Asensus Surgical Inc for the April to June 30, 2023 time-frame, the company's deficit has expanded to $-0.09 per share compared to $-0.08 per share a year ago. Additionally, this represents a continuation of the deficit of $-0.09 per share from the previous reporting season.

Asensus Surgical Inc

The Diminishing Returns: Asensus Surgical Inc Faces Worsening Accounts Receivable Collection Period, Highlighting Challenges in the Medical Equipment & Supplies Industry

Investors in the healthcare sector need to take note of Asensus Surgical Inc's latest financial report, which indicates that the company's ability to collect accounts receivable has worsened since the fourth quarter of 2022. The average receivable collection period has increased to 77 days compared to 74 days in the previous quarter, showing a more challenging environment for the company.
However, it is important to note that Asensus Surgical Inc's performance is still relatively good compared to other companies in the healthcare sector, as some have a higher receivables turnover ratio. Despite the decrease in turnover, the company's ranking has only deteriorated slightly from 2218 to 2450.






 

Asensus Surgical Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com